Navigation Links
SRI International and PhenoMatriX Collaborate to Develop Platin-Based Chemotherapies
Date:12/2/2010

MENLO PARK, Calif., Dec, 2, 2010 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that it is collaborating with PhenoMatriX (PMX), a biotechnology company, on the development of platin-based chemotherapies.  Platin-based drugs such as cisplatin and related analogues are used to treat a variety of cancers and have served as major weapons against solid tumors and other difficult-to-treat cancers since the 1970s.  Cancer is the leading cause of death worldwide.  Although 861 new cancer medicines and vaccines were in development in 2009 (PhRMA report), and many new products have reached patients in recent years, cancer that has metastasized remains very difficult to treat.  Metastasis occurs in as many as 40 percent of breast cancer cases.

Currently available platin-based drugs are powerful cancer therapies, yet their impact is often diminished by toxicity and resistance, even for newer drugs such as carboplatin and oxaliplatin.  By designing novel therapeutic agents based on an understanding of metabolic cell death pathways and targeting these drugs to mitochondria, PMX has identified effective new platins with lower toxicity.

As part of the collaboration, SRI researchers will perform preclinical research and development (R&D) studies on novel chemotherapeutics provided by PMX and its commercial development partner.  SRI will receive royalties on sales of specific PMX drugs and an equity stake in the company once R&D milestones are met.  PMX will seek additional funding and partnerships to advance its leads into clinical trials and to market.

"Having collaborated with Dr. Steliou on a number of innovative programs for more than a decade, I am pleased to announce this joint effort with PMX around new drugs that have the potential to increase the efficacy of platins while reducing their side effects and decreasing resistance," said Walter Moos, Ph.D., vice president of SRI's Biosciences Division.  "While we are a minimum of two years away from human clinical testing, each step forward builds on our ability to ultimately benefit cancer patients."

"By working with SRI International, an experienced collaborator whose R&D team has discovered and developed multiple anticancer drugs that have entered clinical trials and gained regulatory approval, we hope to achieve similar success with our new chemotherapeutic platins," said Kosta Steliou, Ph.D., founder, president, and CEO of PhenoMatriX.  "It is also a pleasure to continue working with Dr. Moos and his team on new approaches to improving health and saving lives."  

Douglas V. Faller, M.D., Ph.D., the Karin Grunebaum professor of cancer research and director of the Cancer Center at Boston University Medical Center, of which Dr. Steliou is also a member, commented that "Platins have been the mainstay of chemotherapeutic regimens for a variety of solid tumors for many years. There is clearly a need for the development of more potent, but simultaneously less toxic derivatives, particularly derivatives effective against platin-resistant tumors.  These compounds therefore have the potential to benefit many patients with diverse cancers, and represent a particularly promising development for cancer chemotherapy."

About SRI's Biosciences Division

SRI's Biosciences division carries out basic research, drug discovery, and drug development, and provides contract research organization (CRO) services.  SRI has all the resources necessary to take R&D from "Idea to IND"®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience.  SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages.  In its CRO business, SRI has helped government and commercial clients and partners advance many drugs into patient testing.  SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International is one of the world's leading independent research and technology development organizations.  SRI, which was founded by Stanford University as Stanford Research Institute in 1946 and became independent in 1970, has been meeting the strategic needs of clients and partners for more than 60 years.  Perhaps best known for its invention of the computer mouse and interactive computing, SRI has also been responsible for major advances in networking and communications, robotics, drug discovery and development, advanced materials, atmospheric research, education research, economic development, national security, and more.  The nonprofit institute performs sponsored research and development for government agencies, businesses, and foundations.  SRI also licenses its technologies, forms strategic alliances, and creates spin-off companies.  In 2009, SRI's consolidated revenues, including its wholly owned for-profit subsidiary, Sarnoff Corporation, were approximately $470 million.  Sarnoff Corporation, a leader in vision, video, and semiconductor innovations, will be fully integrated into SRI effective January 1, 2011.


'/>"/>
SOURCE SRI International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Draeger Teams Up with International Aid to Supply Medical Equipment for Use in Developing Countries
2. Varian Medical Systems to Display Medical X-Ray Tubes and PaxScan® Digital X-Ray Image Detectors at MEDICA 2010 International Trade Fair
3. VIDEO from International Osteoporosis Foundation available on thenewsmarket.com: IOF Focuses on WHO Fracture Risk Assessment Tool for International Discussions
4. SRI International Executive Walter Moos to Discuss Collaborative Pharmaceutical Opportunities with a Nonprofit Organization at BIO-Europe 2010
5. PRA International Expert to Chair Panel at Partnerships Conference
6. Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results
7. Joseph Perrone Joins SRI International to Direct Molecular Diagnostics and Rare and Neglected Diseases Group
8. Dehaier Medical to Participate in MEDICA International Trade Fair
9. Microfluidics International Corporation to Report Third Quarter 2010 Financial Results on November 16, 2010
10. Systech International and Vantage Consulting Group Partner to Address Emerging U.S. Pharmaceutical Regulatory Requirements
11. PAREXEL International to Participate in the Lazard Capital Markets Healthcare Conference in New York and the Jefferies Healthcare Summit in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):